Hutchison China Meditech expands collaboration with Innovent
(Sharecast News) - Hutchison China Meditech on Thursday confirmed the expansion of its tumour treatment collaboration agreement with Innovent Biologics Inc..
Read moreTue, 13th Jul 2021 15:42
(Sharecast News) - Hutchison China Meditech on Thursday confirmed the expansion of its tumour treatment collaboration agreement with Innovent Biologics Inc..
Read moreHutchison China Expands Tumour Treatment Collaboration With Innovent
Read more(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated an international phase 1 and 1b study of 'HMPL-523' - its novel spleen tyrosine kinase inhibitor - in patients with relapsed or refractory lymphoma, it announced on Friday.
Read moreWINNERS & LOSERS SUMMARY: Astra Rises On Fasenra Approval In US
Read moreHutchison China Doses First Patient In HMPL-523 Lymphoma Study
Read more(Alliance News) - Hutchison China MediTech Ltd said Tuesday it has started its phase 1/1b study of small molecule inhibitor HMPL-689 in patients with advanced relapsed or refractory in the firm at
Read more(Sharecast News) - Hutchison China MediTech has launched a clinical trial of HMPL-523, a novel spleen tyrosine kinase inhibitor, in patients with immune thrombocytopenia, an autoimmune disorder that can lead to increased risk of bleeding.
Read more(Alliance News) - Hutchison China Meditech Ltd on Friday said it has begun a phase 1 study of HMPL-523 as a treatment for immune thrombocytopenia in China, dosing the first patient on Monday last
Read more(Alliance News) - Hutchison China MediTech Ltd on Tuesday said its loss widened in the first half of the year due to expenses, while it has reduced guidance on expenses and cash flow.Shares
Read moreWednesday 24 July Tullow OilHalf Year ResultsPaypointQ1 Year ResultsLaw
Read more(Alliance News) - Hutchison China Meditech Ltd on Wednesday said Prudential PLC held a 5.1% stake in the China-focused drug company.Following a deal on Friday last week, Prudential held in
Read more(Alliance News) - China-focused drug developer and distributor Hutchison China Meditech PLC said Friday the pricing of a secondary offer of its Nasdaq-listed shares has been fixed at USD24.00 also
Read more(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee (IDMC) of the phase 3 pivotal study of 'surufatinib' in advanced neuroendocrine tumors - extra-pancreatic (SANET-ep) had completed a planned interim analysis.
Read moreLONDON (Alliance News) - Hutchison China Meditech Ltd on Wednesday said its shareholders have approved a subdivision of shares at its extraordinary general meeting.The pharmaceutical that a
Read moreThursday 18 AprilDomino's Pizza GroupSEGRORPC Group (re acquisition by Berry 19 events 22 events 23
Read more